Descriptions:
Oura CEO Tom Hale speaks at the Cancelo Sparks Summit 2026 about the company’s multi-year AI investment and its roadmap toward FDA-regulated medical device status. Oura’s current AI capabilities center on short-term health predictions — illness onset two to three days out, menstrual cycle timing — with Hale describing the longer-term ambition as using continuous biometric data to help users understand how daily behaviors influence health outcomes and, ultimately, healthcare costs at a population level.
A key disclosure is Oura’s blood pressure study, currently enrolling nearly 300,000 participants who take cuff measurements alongside ring-based predictions, generating a clinically validated dataset for an FDA submission. Hale confirms active collaboration with FDA’s Center for Devices and Radiological Health (CDRH) across multiple submissions, noting that Oura will operate as a general wellness device — providing insight rather than diagnosis — until those submissions clear. He describes the leadership gap at the FDA as having no material impact on Oura’s working relationship with the agency’s technical staff.
On the competitive landscape, Hale notes that roughly two-thirds of Oura ring wearers also own an Apple Watch, framing the two companies as complementary despite significant talent crossover. Asked about AI disruption to the software industry, he offers a memorable framing for Oura’s hardware-first positioning: ‘you can’t vibe code atoms’ — arguing that hardware companies have become unexpectedly attractive to investors as AI compresses pure-software margins.
📺 Source: Bloomberg Technology · Published May 14, 2026
🏷️ Format: Interview
